We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current YP1B market cap is 232.08M. The company's latest EPS is AUD -0.0454 and P/E is -9.47.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 140k | 7.49M | 0 | 170k | 0 |
| Operating Income | -19.24M | -14M | -19.66M | -33.84M | -41.43M |
| Net Income | -18.34M | -13.47M | -29.9M | -32.21M | -39.9M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 40.54M | 46.6M | 82.03M | 102.17M | 147.45M |
| Total Liabilities | 16.15M | 13.3M | 8.76M | 8.09M | 10.98M |
| Total Equity | 24.39M | 33.3M | 73.27M | 94.08M | 136.47M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -15.29M | -10.84M | -17.64M | -30.23M | -35.36M |
| Investing | -41k | -19k | -16k | -22k | -83k |
| Financing | 8.01M | 20.48M | 52.68M | 50.33M | 76.02M |
| Market Cap | 232.08M |
| Price to Earnings Ratio | -9.47 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 3.06 |
| Price to Book Ratio | 2.77 |
| Dividend Yield | - |
| Shares Outstanding | 879.09M |
| Average Volume (1 week) | 13.5k |
| Average Volume (1 Month) | 14.3k |
| 52 Week Change | 60.98% |
| 52 Week High | 0.30 |
| 52 Week Low | 0.154 |
| Spread (Intraday) | 0.02 (7.91%) |
| Company Name | Immutep Limited |
| Address |
level 12 sydney, new south wales 2000 |
| Website | https://www.immutep.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
